Αποτελέσματα Αναζήτησης
30 Αυγ 2021 · The relative female predominance for neutropenia at age ≥ 60 years (934/1282; 73% of cases) was also consistent with relatively lower neutrophil levels for women in these age categories (mean, 3.0 ± 1.0 vs 3.3 ± 1.1 in males; P < .001) (Figure 1G-I).
16 Απρ 2019 · Neutropenia is a well-recognised complication of chemotherapy, associated with an increased risk of infection, febrile neutropenia (FN), and as a consequence, can lead to mortality . Interventions to prevent neutropenic events (NEs) such as FN can reduce incidence and associated complications.
27 Απρ 2023 · Exceptions for baseline BM evaluations are summarized as follows: (a) newborns with a family history of CN with a known gene mutation, where the genetic analysis may be performed first, but does not replace subsequent BM evaluation; (b) infants with positive antineutrophil antibodies and no history of bacterial infections, where a BM evaluation ...
15 Ιαν 2023 · Continuing Education Activity. Neutropenia is a decreased number of neutrophils less than 1500/microliter and can be idiopathic, congenital, autoimmune, or cyclic. Those lasting more than three months without underlying etiology are idiopathic chronic neutropenia.
3 Οκτ 2020 · The primary complications of neutropenia are recurrent and fatal bacterial, viral, and fungal infections. Another major concern is the development of myelodysplastic syndrome or acute myeloid leukemia, the risk of which is especially high in congenital neutropenias secondary to mutations in ELANE, HAX1, WAS, GATA2, G6PC3, and SBDS.
9 Απρ 2024 · The most common and important diseases affecting neutrophil production are severe congenital neutropenia and cyclic neutropenia. Common variable immunodeficiency is the most common immunodeficiency encountered.
29 Νοε 2010 · The average age of included patients was 59.8 years (range, 18-97 years) with 1445 (38.4%) aged 65 and older. Seventy percent (70%) of patients were female with breast cancer representing the most common malignancy (39%) followed by lung cancer (24%), colorectal (14%), lymphoma (15%), and ovary (8%).
